Treatment News : Stribild Is as Safe, Effective as Atripla, Even Among Less-Adherent

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join

Back to home » Treatment News » October 2012

Most Popular Links
Most Popular Lessons

The HIV Life Cycle


Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

20 Years Ago In POZ

More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to


October 30, 2012

Stribild Is as Safe, Effective as Atripla, Even Among Less-Adherent

Following on the heels of research showing that the new combo pill Stribild, a.k.a. the Quad, is as effective and safe as Atripla, a new study has shown that the two once-a-day therapies also have similar efficacies in those who don’t adhere perfectly to their regimens. Gilead Sciences presented a poster abstract of its study at the IDWeek 2012 meeting in San Francisco comparing Stribild’s and Atripla’s efficacy and safety among patients with a less than 95 percent adherence rate over a 48-week period. (Gilead makes Stribild; working with Bristol-Myers Squibb, it also makes Atripla.) The study found that 25 percent of those taking Stribild or Atripla were less than 95 percent adherent, resulting in 91 percent and 88 percent efficacy, respectively. Seven percent of Stribild users and 10 percent of those on Atripla were less than 90 percent adherent, with a respective efficacy of 79 and 75 percent. Such comparable data may help Stribild—which contains Gilead’s integrase inhibitor elvitegravir, boosted by cobicistat, along with tenofovir and emtricitabine—to position itself as a strong alternative to Atripla (efavirenz, emtricitabine and tenofovir).  

To read the abstract and for a link to a PDF of the poster, click here.

Link for previous research: (

Search: HIV, Stribild, Atripla, Quad, antiretroviral, Gilead Sciences, Bristol-Myers Squibb, IDWeek 2012, efficacy, adherence

Scroll down to comment on this story.


(will display; 2-50 characters)


(will NOT display)


(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules

Show comments (0 total)

[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Did you participate in an event for National Black HIV/AIDS Awareness Day 2016?


more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.